Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles (PARKADD)
Behavioural Addictions Occurring During a Dopaminergic Treatment Prescribe Under Parkinson's Disease: Study of the Psychopathological, Neurological, Pharmacokinetic and Genetic Profiles.
This study is composed of a main study and an ancillary one. The objective of the main study is to define, on the psychopathological, neurological, pharmacokinetic and genetic plan, the predictive factors for developing a behavioural addiction (BA) secondarily to the dopaminergic treatment, associated or not to a dopamine dysregulation syndrome (DDS), in patients with Parkinson's disease.
3 particular profiles of patients will be established:
- BA- : no secondary behavioural addiction
- BA+/DDS-: secondary behavioural addiction, without dopamine dysregulation syndrome
- BA+/DDS+: secondary behavioural addiction, with dopamine dysregulation syndrome
We wish in particular:
- To differentiate, among the BA+ subjects, those for who is a DDS from those for who we can evoke a side effect of the dopaminergic treatment
- To demonstrate that the BA+/DDS- subjects present pharmacokinetic particularities causing the occurrence of the BA.
- To clarify the possible relationship between the dosage and the pharmacodynamics of the treatment (especially that of pramipexole) in one hand, and the developing of BA in the other hand.
- Demonstrate that the subjects BA + / DDS- are individually genetic vulnerability (related to the dopamine system), originally from the occurrence of the BA.
This study has several levels of evaluation, we chose describe the methodology of the study in 3 axis : Psychopathology axis, Neurological axis and pharmacokinetic axis.
The pharmacokinetic aspects will be studied only on a part of the sample, in an ancillary study centered on the pharmacokinetic of the pramipexole (in its immediate release form).
Panoramica dello studio
Stato
Intervento / Trattamento
Descrizione dettagliata
This is a monocentric study with a recruitment period comprised between October 2012 and April 2016. The recruitment occurs during the consultations in the service of neurology. If the subjects are eligible, the study is proposed to them, and an evaluation is fixed in the next days. This evaluation consists in an individual face-to-face interview based on standardized and semi-structured questionnaires, during approximately one and a half hour. It's focused on the different characteristics of Parkinson's disease, and on psychiatric and addictive co morbidities. The evaluation is completed by a set of self-administered questionnaires focused on impulsivity and Attention Deficit Hyperactivity Disorder (ADHD).
For the 80 patients participated to the ancillary study only, a blood sample will be realized when the patient will arrived, just before the intake of his treatment (to obtain the residual plasmatic concentration). A second sample will be realized at a different time for each patient, to cover the entirety of the kinetic between 2 intakes of pramipexole (immediate release form) via the entire sample. The second blood sample will be realized four hours after the first one at the most. After this second sample, the patient will have completed his participation to the study.
Secondly, monitoring including a self-questionnaire booklet and a saliva sample will be offered to all patients who completed the initial visit.
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 4
Contatti e Sedi
Luoghi di studio
-
-
-
Nantes, Francia
- Nantes University Hospital
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Main study
Inclusion criteria:
- To be 18 years old or more (both genders)
- To have idiopathic Parkinson's disease, without important cognitive troubles, treated by usually prescribed drugs
- To have a treatment established since 6 months at least
Exclusion criteria:
- To be under tutelage (a French protecting measure for persons with altered judgement)
- To have a secondary Parkinson's disease
- To have received a chirurgical treatment for Parkinson's disease
- To present obvious cognitive disturbances
Ancillary study (pharmacokinetic axis) :
Inclusion criteria:
- The same as the main study
- To have a treatment by pramipexole in the immediate release form
Exclusion criteria:
- The same as the main study
- Association of the pramipexole with others molecules
- To use to have a behavioural addiction resolved by a diminution of the dosage before the study
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Diagnostico
- Assegnazione: Non randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: BA-
Patient with no secondary behavioural addiction
|
Summons of patients and filling questionnaire.
|
|
Sperimentale: BA+/DDS-
Patients with secondary behavioural addiction, without dopamine dysregulation syndrome
|
Summons of patients and filling questionnaire.
|
|
Sperimentale: BA+/DDS+
Patients with secondary behavioural addiction and dopamine dysregulation syndrome
|
Summons of patients and filling questionnaire.
|
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
|---|---|
|
Psychopathological axis : score of sensation seeking (S Score) of the impulsivity questionnaire "UPPS"
|
This choice is founded on the fact that patients suffering of DDS are described as being impulsive, misusing their anti-parkinsonism treatment in the purpose of stimulate themselves, suggesting they have a high level of sensation and novelty seeking.
|
|
Pharmacological axis : Area under the curve of the pramipexole concentration
|
Area under the curve of the pramipexole concentration in function of the time between 2 intakes of pramipexole.
|
|
Neurological axis : Unified Parkinson's Disease Rating Scale (UPDRS) III score
|
UPDRS III score, with axial under-score in ON and OFF DOPA (Parkinson's disease severity)
|
|
Genetic axis : distribution of allele frequencies and genotypic
|
Distribution of allele frequencies and genotypic
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
|---|---|
|
Treatments except the anti-parkinsonism ones
|
Psychopathological axis
|
|
drug misuse
|
Psychopathological axis
|
|
addiction and punding antecedents
|
Psychopathological axis
|
|
ADHD antecedents
|
Psychopathological axis
|
|
impulsivity profile
|
Psychopathological axis
|
|
Age of onset of the Parkinson's disease
|
Neurological axis
|
|
stage and form of the Parkinson's disease
|
Neurological axis included dyskinesia and involuntary abnormal movements
|
|
time course of Parkinson's disease
|
Neurological axis
|
|
family history of Parkinson's disease
|
Neurological axis
|
|
anti-parkinsonism treatments
|
Neurological axis
|
|
Residual plasmatic concentration of the pramipexole
|
Pharmacological axis The data of the pharmacological axis are measured after analyzes of the blood samples collected in that evaluation, only for the 80 patients participated to the ancillary study.
|
|
median pharmacokinetic parameters of pramipexole
|
Pharmacological axis The data of the pharmacological axis are measured after analyzes of the blood samples collected in that evaluation, only for the 80 patients participated to the ancillary study.
|
|
study of the hepatic and renal functions
|
Pharmacological axis The data of the pharmacological axis are measured after analyzes of the blood samples collected in that evaluation, only for the 80 patients participated to the ancillary study.
|
|
Physiopathological covariates
|
Pharmacological axis age, gender, weight, creatinine and prothrombin rates The data of the pharmacological axis are measured after analyzes of the blood samples collected in that evaluation, only for the 80 patients participated to the ancillary study.
|
Collaboratori e investigatori
Sponsor
Investigatori
- Investigatore principale: Marie GRALL-BRONNEC, Nantes UH
Studiare le date dei record
Studia le date principali
Inizio studio
Completamento primario (Effettivo)
Completamento dello studio (Effettivo)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Stima)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Parole chiave
Termini MeSH pertinenti aggiuntivi
Altri numeri di identificazione dello studio
- RC12_0059
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .
Prove cliniche su questionnaires
-
University Hospital, ToulouseCompletatoIpertensione polmonare persistente del neonatoFrancia
-
Mỹ Đức HospitalCompletatoInfertilità | Fecondazione in vitro | IVMVietnam
-
Mỹ Đức HospitalCompletato
-
Mỹ Đức HospitalCompletatoInfertilità | Fecondazione in vitroVietnam
-
Mỹ Đức HospitalCompletatoFIVET convenzionale, ICSIVietnam
-
Mỹ Đức HospitalCompletatoNascita prematuraVietnam
-
Mỹ Đức HospitalReclutamentoSviluppo del bambino | Preparazione dell'endometrioVietnam